AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting

AstraZeneca Plc AZN and Daiichi Sankyo DSNKY reported high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase 2 trial of Enhertu (trastuzumab deruxtecan)
The study met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients.
Related: AstraZeneca-Daiichi Sankyo's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer.
Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC) jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
The DESTINY-PanTumor02 Phase II trial is evaluating the efficacy and safety of Enhertu in patients with locally advanced, unresectable, or metastatic previously treated, HER2-expressing solid tumors not eligible for curative therapy.
Also See: AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs.
Price Action: AZN shares are down 0.94% at $64.59 on the last check Monday.